- Home
- HYPR vs RPTX Comparison
HYPR vs RPTX Comparison
Compare HYPR & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- RPTX
- Stock Information
- Founded
- HYPR 2014
- RPTX 2016
- Country
- HYPR United States
- RPTX Canada
- Employees
- HYPR N/A
- RPTX N/A
- Industry
- HYPR Medical Specialities
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- RPTX Health Care
- Exchange
- HYPR Nasdaq
- RPTX Nasdaq
- Market Cap
- HYPR 54.6M
- RPTX 58.8M
- IPO Year
- HYPR N/A
- RPTX 2020
- Fundamental
- Price
- HYPR $0.80
- RPTX $1.47
- Analyst Decision
- HYPR Strong Buy
- RPTX Strong Buy
- Analyst Count
- HYPR 3
- RPTX 3
- Target Price
- HYPR $1.06
- RPTX $4.50
- AVG Volume (30 Days)
- HYPR 6.2M
- RPTX 152.5K
- Earning Date
- HYPR 05-13-2025
- RPTX 05-13-2025
- Dividend Yield
- HYPR N/A
- RPTX N/A
- EPS Growth
- HYPR N/A
- RPTX N/A
- EPS
- HYPR N/A
- RPTX N/A
- Revenue
- HYPR $11,732,000.00
- RPTX $1,073,000.00
- Revenue This Year
- HYPR $13.22
- RPTX N/A
- Revenue Next Year
- HYPR $24.57
- RPTX N/A
- P/E Ratio
- HYPR N/A
- RPTX N/A
- Revenue Growth
- HYPR 0.34
- RPTX N/A
- 52 Week Low
- HYPR $0.53
- RPTX $0.89
- 52 Week High
- HYPR $1.90
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- HYPR 56.58
- RPTX 63.76
- Support Level
- HYPR $0.61
- RPTX $1.33
- Resistance Level
- HYPR $1.19
- RPTX $1.41
- Average True Range (ATR)
- HYPR 0.12
- RPTX 0.06
- MACD
- HYPR 0.03
- RPTX 0.01
- Stochastic Oscillator
- HYPR 40.06
- RPTX 80.00
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.